153322-05-5

Basic information

• Product Name: LaniceMine
• Synonyms: LaniceMine;2-PyridineethanaMine, a-phenyl-, (aS)-;(1S)-1-phenyl-2-pyridin-2-ylethanamine;(S)-1-phenyl-2-(pyridin-2-yl)ethanamine
• CAS NO: 153322-05-5
• Molecular Formula: C13H14N2
• Molecular Weight: 198.26366
• Mol File: 153322-05-5.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 307.7°Cat760mmHg
• Flash Point: 160.5°C
• Appearance: /
• Density: 1.097g/cm³
• Vapor Pressure: 0.000712mmHg at 25°C
• Refractive Index: 1.601
• Solubility: ≤20mg/ml in ethanol;30mg/ml in DMSO;5mg/ml in dimethyl formamide
• PKA: 8.29±0.10(Predicted)
• CAS DataBase Reference: LaniceMine(CAS DataBase Reference)
• NIST Chemistry Reference: LaniceMine(153322-05-5)
• EPA Substance Registry System: LaniceMine(153322-05-5)

Safety Data

• Hazardous Substances Data: 153322-05-5(Hazardous Substances Data)

Usage

Description

Lanicemine is a non-selective, voltage-dependent N-methyl-D-aspartate (NMDA) channel blocker with an IC50 value of 4-7 μM and a Ki value of 0.56-2.1 μM. It is known for its lower propensity to be trapped within the NMDA channel compared to ketamine, making it a promising candidate for various therapeutic applications. Lanicemine has been investigated for its potential antidepressant effects without causing adverse psychotomimetic activity, as well as its potential as an anti-hypertensive agent.

Uses

Used in Pharmaceutical Industry:
Lanicemine is used as a potential anti-depressant for its ability to produce antidepressant effects without causing adverse psychotomimetic activity. This makes it a promising candidate for the treatment of depression and related disorders.
Used in Cardiovascular Applications:
Lanicemine is used as a potential anti-hypertensive agent, which could be beneficial in the management and treatment of hypertension and related cardiovascular conditions.
Used in Neurological Applications:
As a non-selective voltage-dependent NMDA channel blocker, Lanicemine is used for its potential to modulate neuronal activity and protect against excitotoxicity, which may be useful in the treatment of various neurological disorders associated with overactivation of NMDA receptors.

in vitro

previous study with lanicemine and ketamine found that both compounds could bind with low-to-moderate affinity to sites within the nmda channel pore, exhibit strong voltage dependence, and have similar lack of nr2a vs nr2b subunit selectivity [1].

in vivo

in animal study, cortical eeg recordings were obtained from rats trained to perform an auditory detection task for food reward. results showed that both lanicemine and ketamine produced pronounced dose-dependent elevations in spontaneous gamma-band eeg, but only gamma changes for ketamine were tightly coupled to increases in locomotor activity, indicating that lanicemine not only engaged brain circuits involved in the generation of gamma-eeg, but also influenced these networks independent of the broader systemslevel disruptions typical of ketamine [1].

IC 50

4-7 μm

references

[1] g. sanacora, m. a. smith, s. pathak, et al. lanicemine: a low-trapping nmda channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. molecular psychiatry 19(9), 978-985 (2014).

InChI:InChI=1/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2